Company intelligence / Profile preview
AVIPERO Ltd.
Edinburgh, Scotland, United Kingdomavipero.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Phase 1
01
Overview
AVIPERO is developing allosteric modulators of integrins for treating Triple Negative Breast Cancer and other conditions. Their approach aims to refine integrins and tissues to restore cells to their original state, modifying disease progression while reducing severe side effects associated with traditional treatments. Currently, their pipeline includes AVI-001 and AVI-002, both in preclinical stage.
- Therapeutic areas
- OtherOncologyNeurology
- Modalities
- Small molecule drugAllosteric modulators
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on AVIPERO Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVIPERO Ltd..